Monoclonal Antibodies Market Size, Share, Growth, Analysis, 2034

(MENAFN- Straits Research) Monoclonal Antibodies Market Size

The global monoclonal antibodies market size was valued at USD 292861.03 million in 2025 and is projected to grow from USD 337375.9 million in 2026 to USD 1046487.13 million by 2034 at a CAGR of 15.2% during the forecast period 2026-2034.

The major factors contributing to the growth of monoclonal antibodies industry are the increasing prevalence of cancer and autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis. In addition, technological advancements in genetic engineering and biomanufacturing, such as hybridoma techniques, have increased the efficiency of monoclonal antibodies, which makes them highly popular in cancer management. Furthermore, expanding application of approved monoclonal antibodies in oncology, immunology, and infectious diseases further contributes to the growing demand for monoclonal antibodies, which in turn, boosts the market growth.

For instance, the graph below shows the prevalence of cancer in the U.S., highlighting the year and year growth of cancer cases from 2024 to 2025, which drives the need for effective monoclonal antibodies for its treatment.

Source: American Cancer Society

Monoclonal Antibodies Market Trends Expanding Indications beyond Oncology

An emerging trend in the monoclonal antibodies is growing approvals of previously approved monoclonal antibodies for expanding application, these applications include autoimmune diseases, neurological disorders, and rare diseases. For instance, In July 2024, the U.S. FDA approved Eli Lilly's donanemab (Kisunla), a monoclonal antibody for early-stage Alzheimer's, marking a significant advancement in therapeutic applications beyond oncology. This trend has driven the R&D activities for developing advanced monoclonal antibodies and also increased the demand for the management of various diseases.

For example, the below table indicates the expanded approvals of Enhertu, a monoclonal antibody, to treat various diseases beyond cancer.

Expansion of Label and Indication of Enhertu (trastuzumab deruxtecan)
Year of Approval	Indication
January 2025	Metastatic hormone receptor (HR)-positive, HER2-low breast cancer
April 2024	HER2-positive solid tumours
August 2022	Metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting
May 2022	Metastatic HER2-positive breast cancer who have received prior anti-HER2-based regimen in the metastatic setting
January 2021	Gastroesophageal junction (GEJ) adenocarcinoma

Source: AstraZeneca and DAIICHI SANKYO COMPANY, LIMITED Press Release

Thus, such advancements are driving the demand for monoclonal antibodies to treat various diseases.

Rise of Precision Medicine and Biomarker-Based Therapies

Currently, new mAbs are being developed to bind to specific proteins such as PD-1, HER2, and EGFR. These drugs focus on treatments to individual patient profiles based on genetics. This improves the clinical outcomes, improving efficacy of the drugs products.

For example, Trastuzumab is the only effective in patients whose tumors overexpress the HER2 receptor, this was identified through immunohistochemistry (IHC) testing. In August 2022, the FDA approved trastuzumab deruxtecan (Enhertu) for HER2-low breast cancer, a new molecular classification.

Thus, development of such targeted precision monoclonal antibodies is an emerging trend in the market.

Market Summary

Market Metric	Details & Data (2025-2034)
2025 Market Valuation	USD 292861.03 million
Estimated 2026 Value	USD 337375.9 million
Projected 2034 Value	USD 1046487.13 million
CAGR (2026-2034)	15.2%
Study Period	2022-2034
Dominant Region	North America
Fastest Growing Region	Asia Pacific
Key Market Players	AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Bristol-Myers Squibb Company

Download Free Sample Report to Get Detailed Insights.

Monoclonal Antibodies Market Growth Factors Rising Demand for Monoclonal Antibodies to Treat Chronic Disease Conditions

The rise in the number of people suffering from various chronic diseases, such as cancer, autoimmune disorders, and other rare diseases are driving the need for monoclonal antibodies for effective disease management.

For instance, the graph below highlights the global rise in number of people suffering from cancer and neurologic disorders, highlighting the need for monoclonal antibodies.

Source: World Health Organization & Straits Research

Further, growing incidence of rare diseases such as myasthenia gravis followed by early access authorization further drives the market growth. According to Myology 2022 conference, 20,000 people suffer from myasthenia gravis in France. In addition, ravulizumab (Ultomiris) received approval in May 2022, and efgartigimod (Vyvgart) in July 2022 for the rare disease management, both factors collectively support the market growth.

Thus, as the chronic disease burden is growing, so does the need for monoclonal antibodies rises for efficient disease management.

Growth in Year-on-Year Funding for Monoclonal Antibodies

Government and various organizations are actively providing funding for the development and procurement of monoclonal antibodies is boosting the confidence among manufacturers to invest in the development and production of monoclonal antibodies, which in turn supports the market growth. Thus, providing financial coverage for development and costly treatments helps reduce financial burden and encourages healthcare providers to prescribe these medications.

For example, in September 2024, the University of Texas Medical Branch have been awarded with an amount of USD 15 million per year from National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) to develop vaccines and monoclonal antibodies. In January 2025, Bill & Melinda Gates Foundation (BMGF) in partnership with LifeArc, which is a UK based medical research charity, announced to provide funding for sourcing and seeding innovations as well as accelerating the development of transformational solutions for reducing the costs of monoclonal antibody production. In November 2022, Torgny Stigbrand invests in Lipum, for financing the recently initiated phase I study with SOL-116, which is a humanized monoclonal antibody that blocks Bile Salt-Stimulated Lipase (BSSL), which is a previously overlooked target molecule in the immune system.

Market Restraining Factor High Pricing of Monoclonal Antibodies Impacts Their Adoption

The high cost of monoclonal antibodies is unaffordable by low and middle-income countries also developed countries still facing financial burden due to high cost of the treatment. Thus, availability of alternative therapies for the treatment of these diseases are preferred, which impacts the adoption of monoclonal antibodies

Below graph highlights the cost of few monoclonal antibodies between Switzerland and UK.

Source: Public Eye and National Institute for Health and Care Excellence

Market Opportunity Clinical Trial Momentum: A Key Opportunity to Fuel Innovation

The increasing number of clinical trials for developing monoclonal antibodies presents a significant opportunity for the growth of monoclonal antibodies market during the forecast period.

For example, below are the leading companies operating in the market for monoclonal antibodies have various candidates under pipeline for numerous disease indications.

Table 1: Monoclonal Antibodies Pipeline of U.S.-Based Companies

Company Name	Product Name	Development Phase	Indication
AbbVie Inc.	Elezanumab (ABT-555)	Phase-III	Spinal Cord Injury
AbbVie Inc.	OpSCF	Phase-III	Atopic Dermatitis
AbbVie Inc.	ABBV-181 (budigalimab)	Phase-III	Solid Tumors
AbbVie Inc.	Livmoniplimab (ABBV-151) + Budigalimab (ABBV-181)	Phase-III	Liver, Solid Tumors, Non-Small Cell Lung Cancer
AbbVie Inc.	TTX-030	Phase-III	Advanced Pancreatic Cancer
AbbVie Inc.	ABBV-141	Phase-II	Idiopathic Pulmonary Fibrosis
AbbVie Inc.	ABBV-142	Phase-II	Idiopathic Pulmonary Fibrosis
Otsuka America Pharmaceutical, Inc	Sibeprenlimab	Investigational New Drug Application Submitted	IgA Nephropathy
Merck & Co., Inc.	Clesrovimab (MK-1654)	Under Review	Respiratory Syncytial Virus
Merck & Co., Inc.	KEYTRUDA (MK-3475)	Under Review	1L Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Under Review	Hepatocellular carcinoma (EU)
Under Review	Ovarian Cancer
Under Review	Small Cell Lung Cancer
Phase- III	Advanced Solid Tumors
Phase- III	Prostate Cancer
Merck & Co., Inc.	Tulisokibart (MK-7240)	Under Review	Crohn's Disease
Under Review	Ulcerative Colitis
Phase- III	Systemic Sclerosis
Merck & Co., Inc.	Boserolimab (MK-5890)	Phase-III	Neoplasm Malignant
Merck & Co., Inc.	Quavonlimab (MK-1308)	Phase-III	Non-small Cell Lung Cancer
Amgen Inc.	Aimovig (erenumab-aooe)	Phase-III	Pediatric Migraine
Amgen Inc.	AMJEVITA (adalimumab-atto)	Phase-III	Interchangeability
Amgen Inc.	BEMARITUZUMAB	Phase- III	Gastric and Gastroesophageal Junction (GEJ) Cancers
Phase- II	Advanced Solid Tumors
Amgen Inc.	EVENITY (romosozumab-aqqg)	Phase- III	Male Osteoporosis
Phase- III	Pediatric Osteogenesis Imperfecta
Amgen Inc.	PROLIA (denosumab)	Phase- III	Pediatric Glucocorticoid-Induced Osteoporosis
Amgen Inc.	Repatha (evolocumab)	Phase- III	Hypercholesterolemia
Amgen Inc.	Rocatinlimab (formerly AMG 451 / KHK4083)	Phase- III	Atopic Dermatitis
Phase- III	Prurigo Nodularis
Phase- II	Asthma
Amgen Inc.	TEPEZZA (teprotumumab-trbw)	Phase- III	Thyroid Eye Disease
Amgen Inc.	TEZSPIRE (tezepelumab-ekko)	Phase- III	Severe Asthma
Phase- III	Chronic Rhinosinusitis with Nasal Polyps
Phase- III	Eosinophilic Esophagitis
Phase- II	Chronic Obstructive Pulmonary Disease
Amgen Inc.	UPLIZNA (inebilizumab-cdon)	Phase- III	IgG4-Related Disease
Phase- III	Myasthenia Gravis
Phase- II	Systemic Lupus Erythematosus with Nephritis
Amgen Inc.	DAXDILIMAB	Phase- II	Dermatomyositis and Anti-synthetase Inflammatory Myositis
Phase- II	Discoid Lupus Erythematosus
Amgen Inc.	ORDESEKIMAB (formerly AMG 714 / PRV-015)	Phase- II	Celiac Disease
Amgen Inc.	AMG 104	Phase-II	Asthma
Amgen Inc.	AMG 329 (formerly HZN-1116)	Phase-II	Sjögren's Disease
Amgen Inc.	AMG 355	Phase- I	Solid Tumors
Amgen Inc.	AMG 691	Phase- I	Asthma
Amgen Inc.	AMG 732 (formerly HZN-280)	Phase- I	Thyroid Eye Disease

Source: AbbVie Inc., Otsuka America Pharmaceutical, Inc., Merck & Co., Inc., Amgen Inc.

Regional Insights

North America dominated the monoclonal antibodies market, accounting for the largest revenue share of 47.09%, owing to availability of major key players in this region, high accessibility to newly launched monoclonal antibodies, well-established reimbursement schemes, and increasing prevalence of chronic diseases such as cancer and autoimmune diseases.

U.s. Monoclonal Antibodies Market Trends

U.S.- monoclonal antibodies industry in U.S. is dominantly growing with rising new cancer cases and prominent regulatory support of U.S. FDA, and presence of major market players. Furthermore, high number of people suffering from Alzheimer's disease potentiates the market growth with increase in demand for monoclonal antibodies as an effective treatment. According to 2024 reports, 6.9 million people from U.S. aged 65 and older are living with Alzheimer's disease and it is estimated to reach 13.8 million by 2060.

Asia Pacific Monoclonal Antibodies Market Trends

Asia Pacific region is anticipated to grow at fastest CAGR of 16.4% during the forecast period. This growth is driven by increasing prevalence of cancer, arthritis, and other diseases, establishment of global pharmaceutical companies in India, and increasing awareness about the efficiency of monoclonal antibodies among healthcare providers.

China – China's monoclonal antibody market has witnessed significant growth, driven by advancements in biopharmaceutical research and regulatory improvements. Furthermore, strong development pipeline over 60 pharmaceutical companies are expected to enhance the treatment accessibility of monoclonal antibodies during the forecast period.

For instance, the below graph highlights the China's strong domestic 142 ongoing R&D projects.

Source: Generics and Biosimilars Initiative (GaBI)

India – India is witnessing strong growth in its monoclonal antibodies market, driven by increasing breast cancer cases. For example, in 2022, according to the Global Cancer Observatory, breast cancer was the leading causes of major cancer cases in India with 192,020 cases. This creates greater adoption of monoclonal antibodies used in treatment such as Herceptin (trastuzumab). Additionally, the increase in government funding for biotechnology research and development is driving the market growth.
For example, in the union budget of 2024-2025 the government of India announced ₹90,171 core for healthcare sector and for research and development to boost local manufacturing and production in the country.

Europe Monoclonal Antibodies Market Trends

UK – The major factors propelling the growth of monoclonal antibodies market in UK is the availability of the investments for the purpose of manufacturing monoclonal antibodies across the country and also owing to the high prevalence of severe diseases such as dementia as well as endometrial cancer, which require monoclonal antibodies for its treatments. For example, in 2022, as per the report of World Cancer Research Fund, total of 420,368 cases of endometrial cancer were witnessed across the globe, in which UK landed in the list of top 10 countries of endometrial cancer cases, which signifies the need for monoclonal antibodies for the treatment of such conditions.
For example, the graph below depicts the cases of dementia across UK in the year 2022 and 2024, which reflects a significant increase among the UK's population.

Sources: Nuffield Trust

Germany – The Germany's monoclonal antibodies industry is rapidly growing owing to is the focus of various research organizations such as German Centre for Infection Research towards the development, production and clinical testing of monoclonal antibodies. In addition, the market is also primarily driven by the high incidences of lung cancer as well as RSV infections across the country. For example, 3,911,800 cases per season of RSV were reported in Germany from the year 2022 to 2023, which reflects the growing need of monoclonal antibodies for the treatment of RSV infection.

Spain– The Spain market is primarily driven by the high prevalence of asthma, availability of well-established production units and growing demand for monoclonal antibodies.

For instance, the below graph highlights some of the most prescribed monoclonal antibodies for asthma are mentioned along with their percentage in the graph below.

Source: National Institutes of Health(NIH)

Type Insights

The market is segmented into human, humanized, murine, and chimeric. Human segment accounted for the largest monoclonal antibodies market share, owing to increasing use of human monoclonal antibodies in cancer and autoimmune diseases, growing approvals of monoclonal antibodies, preference as first-line treatment for cancer, and increasing funding for development of human monoclonal antibodies.

Application Insights

The market is segmented into oncology, autoimmune diseases, hematologic diseases, neurological diseases, infectious diseases, dermatology, others. Oncology segment dominated the market and is expected to register fastest CAGR during the forecast period. This growth is driven by increasing incidences of cancer, use of monoclonal antibodies as a preferred treatment for cancer. Additionally, increasing approvals of monoclonal antibodies for cancer treatment further contribute towards the segment growth.

Distribution Channel Insights

The market is segmented into hospital pharmacies, drug stores & retail pharmacies, and others. Hospital pharmacies segment accounted for maximum revenue share owing to rising incidences of rheumatoid arthritis, colorectum cancer, and infectious diseases, which enhance the demand for new treatments, that lead to availability of monoclonal antibodies as a novel treatment via the hospital care. Furthermore, alliances between hospitals to promote cancer research and development, novel therapies availability with clinical expertise, also increases preference for hospital pharmacies by patients.

Company Market Share

Key players in the industry are majorly concentrated on the development of advanced monoclonal antibodies and are engaged into collaborations among key players for technology transfer to stay competitive in the market.

Accel-Heal Technologies Limited: An Emerging Player in the Monoclonal Antibodies Market

Almirall, S.A. is a Spanish pharmaceutical company emerge as an significant player, owing to its novel monoclonal antibody development and launch of new products.

Recent developments by Almirall, S.A.:

In October 2024, Almirall launched lebrikizumab in Spain for the treatment of atopic dermatitis in adolescents and adults and in February 2024, it received the license from Novartis to develop anti-IL-21 monoclonal antibody in dermatology.

List of Key and Emerging Players in Monoclonal Antibodies Market

AbbVie Inc. Amgen Inc. AstraZeneca plc Biogen Inc. Bristol-Myers Squibb Company Lilly Genmab A/S GlaxoSmithKline plc Johnson & Johnson Merck & Co., Inc. Novartis AG Pfizer Inc. Regeneron Pharmaceuticals, Inc. Roche Holding AG Sanofi S.A. Takeda Pharmaceutical Company Limited UCB S.A.

Recent Developments

In November 2024, Eisai Co., Ltd. and Biogen Inc. launched monoclonal antibody, named as, LEQEMBI, in South Korea, for the treatment of adult patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. October 2024: AGC Biologics received approval for all 2024 biologics applications including monoclonal antibodies from U.S. Food & Drug Administration (FDA). In February 2024, AbbVie and OSE Immunotherapeutics announced partnership in February 2024 for the development of novel monoclonal antibody for the treatment of chronic inflammation.

Analyst Opinion

The Monoclonal Antibodies market is witnessing significant growth, driven by the rising prevalence of chronic diseases, strong product pipeline, intellectual rights for approved products, increasing funding for research, surge in new product approvals, expanding application of monoclonal antibodies to treat various cancers, and improved reimbursement policies that make treatments more accessible.

Report Scope

Report Metric	Details
Market Size in 2025	USD 292861.03 million
Market Size in 2026	USD 337375.9 million
Market Size in 2034	USD 1046487.13 million
CAGR	15.2% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Type, By Application, By Distribution Channel
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM
Countries Covered	US, Canada, UK, Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia

Download Free Sample Report to Get Detailed Insights.

Monoclonal Antibodies Market Segments By Type

Human Humanized Chimeric Murine

By Application

Oncology Autoimmune Diseases Hematologic diseases Neurological Diseases Infectious Diseases Dermatology Others

By Distribution Channel

Hospital Pharmacies Drug Stores & Retail Pharmacies Others

By Region

North America Europe APAC Middle East and Africa LATAM

MENAFN04062026004597010906ID1111213934